In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses how to optimize the treatment of ALK+ non-small cell lung cancer (NSCLC), with a special focus on how practitioners from different European countries may have to approach this problem differently. She touches on policy, drug availability, and certain clinical considerations which might alter the ideal treatment plan.
Optimizing treatment of ALK+ NSCLC: clinical realities
